Objective: To synthesize clinically meaningful herb–statin interactions involving CYP3A4 and transporters, assess the certainty of current evidence, and propose a cautious practice-oriented framework for statin selection and safety monitoring.
Methods: A structured narrative review was conducted using PubMed/MEDLINE, Google Scholar, recent consensus or guidance documents, and reference tracking through January 2026. Priority was given to human studies, case reports, interventional studies, and pharmacokinetic investigations directly addressing herb/food–statin interactions mediated by CYP3A4 or transporters. .
Results: The strongest evidence involves grapefruit with simvastatin or lovastatin; inhibition of intestinal CYP3A4 increases statin exposure and may raise the risk of muscle toxicity in susceptible individuals. Moderate evidence exists for St John’s wort, which induces CYP3A4 and may reduce exposure and lipid-lowering efficacy of simvastatin or atorvastatin, whereas pravastatin appears less affected. Evidence for EGCG–rosuvastatin remains limited and formulation-dependent. Red yeast rice should be considered separately because it contains monacolin K, a lovastatin-like compound, which may increase the risk of additive muscle toxicity when combined with prescription statins.
Conclusion: Herb–statin interactions are mechanistically plausible, but the evidence base remains limited. Therefore, favoring statins less dependent on CYP3A4, avoiding products with statin-like activity, and monitoring muscle symptoms should be regarded as cautious practice guidance rather than formal guideline recommendations.